Recon: Pfizer to buy 8.1% stake in Valneva, Merck explores Seagen buyout
Welcome to Regulatory Reconnaissance, your daily regulatory news and intelligence briefing.In Focus: US
- COVID vaccine rollout for US children close after CDC panel vote (Reuters)
- Lawmakers ask GAO to probe pharmacy benefit managers over their role in drug pricing (STAT)
- Comparing the Pfizer and Moderna Covid vaccines for young children (STAT)
- Merck Explores Purchase of Biotech Seagen (WSJ)
- FDA advisors mostly agree that Acadia’s Nuplazid isn't effective at treating Alzheimer’s-related psychosis (Endpoints)
- Pfizer to buy 8.1 percent stake in French vaccines company Valneva (Reuters)
- EU drugs watchdog begins review of Moderna's variant COVID vaccine (Reuters)
- WHO panel backs use of Omicron-adapted vaccine as booster dose (Reuters)
- Greece Files Graft Lawsuit Against Novartis: Minister (Barron’s)
- FTC could sanction AstraZeneca over alleged collusion (The Korea Herald)
- China Tweaks On-Site Inspection Priorities As Registration Filings Soar (Endpoints)
- BioNTech chief calls for speedy ruling on Covid vaccines that target latest strains (FT)
- Global regulators work towards strengthening collaboration on observational research beyond COVID-19 pandemic (EMA)
- EMA Management Board: highlights of June 2022 meeting (EMA)
- Never forget that early vaccines came from testing on enslaved people (STAT)
- WTO's IP waiver for vaccines is out and the response is generally negative — from all sides (Endpoints)
- J&J inks clinical trial deal with Stand Up To Cancer, latest pharma to join cancer nonprofit study efforts (Endpoints)
- Pushing for top spot in Big Pharma, AbbVie lands a key approval for its blockbuster Skyrizi (Endpoints)
- More drug, fewer jabs: Novartis' Sandoz eyes EMA nod for high-concentration Humira copy (Fierce)
- Teetering on the brink, Clovis abandons an early approval for Rubraca (Endpoints)
- EU Proposes Changes To Labeling Of Investigational Drugs Under Clinical Trial Regulation (Pink Sheet)
- Morcellation Containment System Guidance Stresses Leak Detection, Prevention (MedtechInsight)
- The Pace Of Cyberattacks Is Accelerating. Can Regulators Keep Up? (MedtechInsight)
- MDR And IVDR – Similar Step Ups, Varying Commercial Impacts (MedtechInsight)
- Bristol Myers petitions the Supreme Court in a final bid to prove Gilead's Kite infringed on CAR-T patents (Endpoints)
- Generic Co. Asks Fed. Circ. To Undo Loss In Takeda IP Fight (Law360)
A story’s inclusion in Regulatory Recon does not imply endorsement by Regulatory Focus or RAPS.
